Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesClarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.495 AUD -0.10 ( 6.56%)
Last update at 2026-11-06T05:15:00Z
VOLUME
2483676
Market Cap
596.93M

Momentum Score

…

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.47
Low
1.54
High
52 Week Price Range
1.34
Low
4.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Clarity Pharmaceuticals is an Australian developer of targeted radiopharmaceutical therapies and molecular imaging agents for oncology. Long-term growth may be supported by secular expansion of precision oncology and radioligand therapeutics, plus potential regulatory approvals and commercial partnerships, making the company of interest to investors seeking exposure to a specialist cancer diagnostics and treatments.

Material risks include clinical and regulatory failure, ongoing capital requirements, complex radioisotope manufacturing and supply-chain constraints, and competitive pressure from larger oncology and radiopharmaceutical firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.60
Dividend Yield
-
Revenue TTM
10.53M
Revenue Per Share
0.03
Gross Profit TTM
10.53M
Debt / Equity
-
ROE
-77.55%
Net Debt
-178.25M
ROCE
-63.68%
Diluted EPS TTM
-0.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -116.81M -63.88M -42.03M -24.50M -23.74M
Net income -107.14M -64.30M -42.32M -24.60M -23.75M
Selling general administrative - 11.51M 10.35M 4.71M 9.07M
Selling and marketing expenses - 0.17M 0.17M - -
Gross profit -0.28M 9.46M 11.51M - -
Reconciled depreciation - 0.19M 0.15M 0.10M 0.05M
Ebit -118.91M -69.09M -44.80M -26.36M -30.29M
Ebitda -118.62M -68.91M -44.65M -36.06M -30.24M
Depreciation and amortization 0.28M 0.19M 0.15M - 0.05M
Operating income -118.91M -69.09M -44.80M -24.50M -30.29M
Other operating expenses 118.91M 78.56M 56.31M - 30.29M
Interest expense - - - - 0.00M
Tax provision - 0.42M 0.30M 0.10M 0.02M
Interest income - 4.76M 2.77M 1.86M 0.10M
Net interest income - 4.76M 2.77M 1.86M 0.10M
Income tax expense -9.67M 0.42M 0.30M 0.10M 0.02M
Total revenue - 9.46M 11.51M 11.66M 6.55M
Total operating expenses 118.62M 78.56M 56.31M - 30.29M
Cost of revenue 0.28M - 0.15M - -
Total other income expense net 2.10M 5.22M 2.77M 9.80M 6.46M
Net income from continuing ops - -64.30M -42.32M -24.60M -23.75M
Net income applicable to common shares - -64.30M -42.32M -24.60M -23.75M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 199.06M 101.17M 154.63M 76.90M 99.82M
Other current assets 7.41M - 4.92M - -
Total liab 12.96M 10.94M 8.33M 7.72M 7.59M
Total stockholder equity 186.11M 90.23M 146.30M 69.18M 92.24M
Other current liab 8.72M - 6.00M 0.48M 4.66M
Common stock 450.96M - 249.45M 132.82M 132.12M
Capital stock - 255.89M - 132.82M 132.12M
Retained earnings -284.12M -176.99M -112.70M -70.37M -45.80M
Other liab - - - 0.18M 0.08M
Other assets - - - 0.01M 0.01M
Cash 178.25M 47.68M 136.51M 5.97M 55.34M
Cash and equivalents - - - 25.24M 25.00M
Total current liabilities 12.34M 10.38M 8.09M 7.54M 7.51M
Net debt -178.25M - -136.51M - -55.34M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - - - 6.73M 5.92M
Property plant equipment - - - 0.21M 0.26M
Total current assets 198.49M 100.61M 154.06M 76.68M 99.55M
Long term investments - 0.01M - 0.01M 0.01M
Net tangible assets - - - 69.18M 92.24M
Short term investments - 36.43M - 33.80M 37.00M
Net receivables 12.82M - 12.63M 10.00M 6.66M
Accounts payable 3.62M 3.21M 2.08M 2.85M 2.85M
Accumulated other comprehensive income 19.27M - 9.55M - 5.92M
Non currrent assets other 0.01M - 0.01M - -
Non current assets total 0.58M 0.57M 0.57M 0.22M 0.27M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 51.99M -55.31M 3.20M -26.50M
Change to liabilities - - - 0.02M 4.93M
Total cashflows from investing activities -84.92M 51.99M -55.31M 3.15M -26.71M
Total cash from financing activities 192.96M 2.21M 115.21M 0.23M 86.93M
Change to operating activities - - - -0.92M -0.01M
Net income -107.14M -64.30M -42.32M -24.60M -23.75M
Change in cash 94.14M -0.22M 16.69M -24.12M 46.90M
Begin period cash flow 84.12M 47.90M 31.21M 55.34M 8.44M
End period cash flow 178.25M 47.68M 47.90M 31.21M 55.34M
Total cash from operating activities -92.55M -54.77M -43.24M -27.50M -13.31M
Issuance of capital stock - 2.40M 121.84M 0.18M 92.40M
Depreciation 0.28M - 0.15M 0.10M 0.05M
Other cashflows from investing activities -84.61M 52.17M -54.80M 3.20M -26.50M
Change to account receivables -2.72M 2.54M -2.63M -3.34M -3.29M
Sale purchase of stock - -0.19M -6.65M 0.24M -5.60M
Other cashflows from financing activities - -0.19M 0.02M -0.01M 0.13M
Change to netincome - - - 1.25M 8.77M
Capital expenditures 0.31M 0.18M 0.50M 0.05M 0.21M
Change in working capital -1.79M 3.22M -5.50M 8.31M 3.34M
Stock based compensation - - 4.17M - -
Other non cash items 16.11M -57.99M 4.59M - -
Free cash flow -92.85M -54.95M -43.74M -27.55M -0.21M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CU6
Clarity Pharmaceuticals Ltd		 -0.10
6.56%		 1.50 - - 56.71 2.95 -0.78
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 -9.86

Profile*

Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

National Innovation Centre, Sydney, NSW, Australia, 2015

61 2 9209 4037

https://www.claritypharmaceuticals.com

100

Name Title Year Born
Dr. Alan John Taylor Ph.D. Exec. Chairman NA
Dr. Colin David Biggin Ph.D. MD, CEO & Exec. Director NA
Mr. David K. Green BEc., CA Chief Financial Officer NA
Mr. Robert Vickery Company Sec. NA
Dr. Michael D. Ironside Director of Operations NA
Dr. Jeffrey Norenberg Chief Scientific Officer NA
Dr. Ellen van Dam Ph.D. Head of R&D NA
Mr. Shaemus Gleason Exec. VP of US Operations NA
Dr. Robert M. Miller Ph.D. Consultant Chief Medical Officer 1952
Mr. William Cheadle Financial Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…